Array BioPharma Inc. (NASDAQ:ARRY) Files An 8-K Regulation FD Disclosure
Item 7.01
Regulation FD Disclosure.
On March 18, 2019, Array BioPharma Inc. issued a press release announcing that the National Comprehensive Cancer Network© (NCCN©) has updated the Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include BRAFTOVI® in combination with MEKTOVI® andcetuximab or panitumumab as a Category 2a treatment for patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), after failure of one to two prior lines of therapy for metastatic disease. A copy of the press release is included as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.
|
Item 7.01 |
Financial Statements and Exhibits. |
(d)Exhibits
|
ExhibitNo. |
Description |
|
Press release dated March 18, 2019.
|
ARRAY BIOPHARMA INC Exhibit
EX-99.1 2 array_nccncrcpressreleasex.htm EXHIBIT 99.1 Exhibit News Release BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN®) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal CancerBoulder,…
To view the full exhibit click here
About Array BioPharma Inc. (NASDAQ:ARRY)
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.
